Effect of Losartan drug on pulmonary fibrosis induced by Bleomycin in experimental rats

Mahdi m.Th.¹*, maha K. Ibrahim²

¹Department of Basic science, College of nursing, Thi-Qar University, Iraq
²Department of Biology, College of science, Basra University, Iraq

Abstract: The present study investigated the protective effect of losartan (Angiotensin 11 inhibitor AT1) administration against bleomycin-induced pulmonary fibrosis in adult male rats. A total of 40 male adult albino rats (Rattus norvegicus) weighing from 200-300 gm each, were divided into four groups of (10) animals each. The first group received a daily intraperitonial (i.p) injection of vehicle normal saline (0.5ml/animal, daily to end experiment), and served as control group. Animals in the second, third and fourth groups were administrated i.p. with bleomycin (15mg/kg/3times weekly for 3 wks), losartan (50mg/kg orally daily to end experiment) and losartan a combination with bleomycin simultaneously to end experiment, respectively.

The present study, declared that the biochemical results determined the levels of Superoxide dismutase (SOD), Glutathion peroxidase (GSHpx) and Hydroxyproline(HYP) content in blood serum of animals. Where after oral administration of losartan in combination with bleomycin, showed that losartan significantly increase SOD P˂0.008 and GSHpx P˂0.001 levels, and decreased HYP P˂0.001 contents in blood stream of the rats in comparison with bleomycin group. Conversely, study showed After intraperitonial injection of bleomycin alone, decreased level of SOD, GSHpx and increased of HYP content in blood serum of rats in comparison of control group. On the other hand, microscopical observations clarified that bleomycin injection showed that inflammatory cells infiltration and fibrotic scores were more prominent, in addition to that, atelected alveoli with damage to lung architecture as well as collagens deposition around patches of alveoli and peribronchioles in the model group compared to the control group, oral administration of losartan in combination with bleomycin, showed marked attenuated the severity of bleomycin –induced pulmonary fibrosis, where identified by reduce the inflammatory cells infiltration whether intraaleveolar or interalveolar septa.

This investigation has clearly identified the importance role of losartan as inhibitor factor on pulmonary fibrosis induced by blm, therefore the findings may be offer one of therapeutic strategy to prevent the lung fibrosis in experimental model.

Keywords: Losartan, pulmonary fibrosis, Bleomycin.

Introduction

Pulmonary fibrosis (PF) is a progressive interstitial lung disease with a high mortality rate and no effective treatment to date¹,². The progression of pulmonary fibrosis results in the widening of interstitial matrix, and eventually in the compression and destruction of normal lung parenchyma³. This disease characterized by loss of lung's architecture through increased epithelial cell apoptosis and abnormal wound repair, lead to the formation of fibroblast –myofibroblast foci and an extracellular matrix deposition⁴,⁵. Experimental lung fibrosis induced by bleomycin is a well studied model of fibrogenesis supported by ample literatures. This model of pulmonary fibrosis resemble that seen in humans and had been used to assessed the
effect of potential therapeutic agents. It has been used successfully to treat a variety of malignancies including squamous cell carcinoma of testis, head, neck, cervix, esophagus germ cell tumors and both Hodgkin, non-Hodgkin lymphoma. The limitation of bleomycin for life-threatening interstitial pulmonary fibrosis (also called fibrosing alveolitis) in up to 10 percent of patients receiving the drugs. Specific treatments for fibrotic lung diseases are not yet available, and are limited to the control of inflammatory events in the lung with the expectation that prevention of inflammation might delay the progression of fibrotic events. The hormone angiotensin 11 is produced primarily in the lung and serve as a putative inducer of TGF-β expression, it may not only up-regulate TGF-β, but expression, but may also alter TGF-β receptors in various models of tissue fibrosis. Indeed the anti-fibrotic activity of angiotensin receptors blockers, such as losartan may significantly contribute to their therapeutic benefit in patients with cardiovascular and renal disease. It is known that losartan, a selective AT1 receptor antagonist, inhibits the proliferation of human lung fibrotic fibroblast induced by ANG11 in vitro. Moreover, losartan inhibits the collagen deposition in the rat model of bleomycin induced pulmonary fibrosis. It has been reported that Prostaglandins is a potent inhibition of fibroblast differentiation. At large, from the aforementioned, administration of losartan leads to, increase PGE and decrease ANG11, so that both of these two processes together lead to an inhibition of fibroblast proliferation and collagen synthesis. Therefore, the main objective of this study was investigated to clarified the impact of losartan on the induction of pulmonary fibrosis in rats.

**Experimental Animals**

Male wisteralbino Wister rats (Rattus norvegicus) weighing 200-250 gm were obtained from animal center of Thi-Qar university college of science. All animal were allowed to take food and received tap water ad libitum, temperature (22±3) with an alternating cycle of 12-h light and dark. Animals were equally distributed into four groups (10 rats) in each experiment;

Group1: Control group, the animals received sterile saline solution 0.5ml/animal daily i.p to end experiment.
Group2: Induction group, the animals received bleomycin 15mg/kg i.p. three times weekly for 3wks.
Group3: Animals received losartan at a dose 50mg/kg daily for end experiment.
Group4: Animals received bleomycin and losartan together simultaneously at doses, periods and administration similar to groups 2 and 3 so that mentioned above.

The dose level and schedule were based on previous studies. The animals were starved over night for 12hrs. Before blood was collected, rats were anaesthetized with chloroform and venous blood samples were collected by direct heart puncture into sterilized tubes (without anticoagulant to separate the sera and then keeping in freezer to determine some biochemical parameters like SOD, GSHpx and HYP, and (with anticoagulant) to procedure rapid hematological examination.

**Biochemical parameters**

**Measurement of GSHpx, SOD and HYP**

The serum glutathione peroxidase (GSHpx), superoxide dismutase (SOD) and hydroxyproline (HYP) were measured on the basis of the instruction of kit for each, that is, Cusabio Eliza kit, catalo no. CSB-E121144r. Briefly use a human serum tube or a serum separator tube (SST) and allow samples to clot for 30 minutes before centrifugation for 15 minutes at 3000 rpm remove serum and assay immediately or aliquot and store samples at -20 c° until required samples were read to absorbance at 450 nm.

**Histopathological examination**

Lung tissue samples were obtained from sagittle slices of the lungs, were fixed in 10% formalin for 24 and then washed –dehydrated-cleared and embedded in paraffin, sections about 4μm thickness was cutting stained with hematoxylin –Eosin for microscopic examination. The histological changes were evaluated by observe of lesions microscopically.

**Statistical analysis**

All values were expressed as mean ±SD with 95% confidence intervals (CI) of experiment statistical analysis of variance (ANOVA) followed when differences were significant. Differences between groups were testing using the paired students T-test. Differences were considered statistically significant at P<0.05.
Results

Biochemical parameters

Table 1: Effect of losartan on superoxide (SOD), glutathione peroxidase (GSHpx) and hydroxyproline (HYP) in blood serum of rats with pulmonary fibrosis (mean±S.D).

<table>
<thead>
<tr>
<th>Groups</th>
<th>SOD μg/ml</th>
<th>GSHpx mIU/ml</th>
<th>HYP μg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>9.42±1.08</td>
<td>33.18±3.44</td>
<td>1.44±0.204</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>7.77±0.644a</td>
<td>17.04±1.52a</td>
<td>2.86±0.125a</td>
</tr>
<tr>
<td>Losartan</td>
<td>9.06±0.78</td>
<td>28.63±1.20</td>
<td>1.25±0.185</td>
</tr>
<tr>
<td>Blm+losartan</td>
<td>8.17±0.969b</td>
<td>29.06±7.814b</td>
<td>1.24±0.342b</td>
</tr>
</tbody>
</table>

Hyp: a p<0.0001 vs. control group, b p<0.0001 vs. blm group.
SOD: a p<0.008 vs. control group, a p<0.05 vs. blm group.
GSHpx: a p<0.001 vs. control group, b p<0.02 vs. blm group.

Results of recent study showed, effect of bleomycin injection on Hydroxyproline content in blood serum were significantly increase in rats with lung fibrosis compared to control group P<0.0001. This rise were markedly inhibited by administrate of losartan in combination with bleomycin p<0.0001(table 1 and fig.1) in compared to bleomycin group. Effect of losartan on antioxidant enzymes include SOD and GSHpx in blood serum of rats with pulmonary fibrosis showed a depletion of SOD activities in the blood serum of Bleomycin group, where SOD activity was significant decrease compared with the control group at P<0.008, that depletion of SOD activity after administrate of losartan with bleomycin significantly prevented the depletion of SOD activity P<0.05 (table 1 and fig.2). Furthermore, bleomycin treatment produced a significant decrease in blood serum GSHpx level at P<0.0001, in rats with pulmonary fibrosis, but use losartan with bleomycin caused significant attenuated of the bleomycin–induced pulmonary fibrosis in the GSHpx level P<0.02 (table 1 and fig.3).
Histopathological findings

Lungs sections of normal rats showed the respiratory portions composed of pocket like sacs called alveoli, also each neighboring alveoli separated by walls known as interalveolar septum with normal alveolar spaces and normal alveolar thickening septa (fig.4). The lungs of rats treated with bleomycin showed alveolar wall thickness, areas of inflammatory infiltration cells mainly lymphocytes, neutrophils and fibroblasts, and collapsed alveoli with marked damage in lung architecture, in addition, there was an excessive amount of collagen deposited around some areas of alveoli and bronchioles (fig.5). Observation on lungs related to rats treated with both bleomycin and losartan showed declared marked suppression of inflammatory cellular evidenced by reduced interstitial infiltrations, less collagen deposition and less thickening in septal walls, also these septa appeared more wide (fig.6).

Fig.4:- Section in the Normal lung parenchyma from saline treated rats (control). Showing alveolar spaces (a) and alveolar septum (arrow), branch of respiratory bronchiole (two arrow).

Fig.5:- Section in the lung of rats treated with bleomycin marked thickening in alveolar septa, numerous mononuclear inflammatory cells and with deposition collagen fibers (arrow), collapsed alveolar narrow spaces (thick arrow), and markedly proliferation of fibroblasts after 21 days bleomycin injection, partial or complete obliteration of alveolar spaces (head thick arrow).
Fig.6: Section in the lung of rats treated with bleomycin-Losartan, marked reduction showing in mononuclear inflammatory cells (white arrow), reduction of thickening of the alveolar septa (black arrow), more patent alveolar spaces (a) and reduction of collagen deposition compared to bleomycin group.

Discussion

To date, controversy exists whether blockad of losartan (AT1) can attenuate the development of lung fibrosis in animals models and delayed its progression, where losartan inhibits angiotensin type 11 which lead to decrease TGF-β production, followed by decrease pulmonary fibrosis progression (14,15).

In the present experiment, we examined the effect of losartan on pulmonary fibrosis induced by intraperitonial injection with bleomycin (15mg/kg). Bleomycin could result an increased AGT11 concentration in lung tissues. In fact, AGT11 also resulted in the production of free radicals, in the model of myocardial infarction, liver fibrosis, and AT1 receptor blockers could prevent the progression of the above mentioned organ injury induced by free radicals. However, the present study showed that bleomycin exposure caused significant increase HYP and decrease in anti-oxidant enzymes activities in blood serum in rats with pulmonary fibrosis. Which where attenuated by losartan, indicated that the effect of losartan lung fibrosis was associated with free radicals scavenging and antioxidant activity. The study shows that losartan significantly decrease lung inflammatory infiltration. After bleomycin exposure, the inflammatory effects of AT1 receptors blockade has been reported in previous studies. Our findings; agreed with those who showed that candesartan attenuated hydroxyproline in lung tissue induces by bleomycin injection. In contrary, decrease of antioxidant enzymes SOD, GSHpx. Our study confirmed that losartan is effective in reduce lung fibrosis induced by bleomycin.

Histological results referred that administration of bleomycin increase collagen deposition and histological changes in lung tissue with high degree of fibrosis. This was in agreement with findings reported previously, namely, bleomycin was increased hydroxyproline level in blood serum in rats with pulmonary fibrosis. Administration of losartan resulted in significant reduction in the marked HYP concentration and reduced the increase in lung coefficient without reaching those of control animals. In the current study, antioxidant enzymes were decreased in bleomycin treated rats while treatment with losartan induced a significant increase in antioxidant enzymes compared to bleomycin group. In agreement, HYP and antioxidant enzymes (SOD, GSHpx) expression were up regulated in fibrotic lung. Whereas losartan reduced the HYP level in bleomycin-induced lung injury–treated rats. Additionally, histological examination showed that losartan could inhibit the progression of lung fibrosis induced by bleomycin in adult albino rats (rattus norvegicus) as previously described.

In conclusion, data from this study suggest that protection effect of losartan against bleomycin–induced lung injury could be due to its antioxidant activity, as well as data proposed that the potential for angiotensin 11 receptor blockers as a therapeutic strategy in patient with pulmonary fibrosis may be beneficial. Consequently, the present study results that the losartan ameliorating effect of pulmonary fibrosis induced by bleomycin in rats, and support the harmful role of AT1 receptors in mediating the effects of ANG11 in bleomycin–induced lung injury and fibrosis in rats.
References

2. Douglas WW, Ryu JH, Schroeder DR; Idiopathic pulmonary fibrosis. (2000); Impact of oxygen and colchicine, prednisone or no therapy on survival. Am J Respir Crit Care Med; 161,1172-1178.
6. Krogel C., Mock B., Hengst, and Reissing A.; (2004); In terferon gamma-1b; Therapeutic option in advance IPF? Respiration; 71,656-657.
8. marsh R.D., McAnulty R.J. and Laurent G.; (2000); Ang 11 is mitogenic for human lung fibrosis via activation of the type 1 receptor. Am J Respir Crit Care Med; 161;1999-2004.
10. Serrano -maller A., Clos D., Cortijo J.; (2002); P-selectin upregulation in blm-induced lung injury in rats; effect of N-acetyl-L-cysteine. Thorax; 57;629-34.
17. Friedmon S.L.; The answer : AG11 , th question : (2004); what do inflammation , Oxidant stress and fibrogenesis have in commom? J heptol; 40;1050-1052.
23. Aly mohammad Ahndi; (2005); Inhibition of bleomycin –induced lung damage in mice by curcumin; The Egyptian Journal of histology; Vol.28 , No2; 211-220.